ArticleFrontiers in pharmacology2021

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF

Su Min Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.